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fatality rate in contrast to that reported in the literature.
Perhaps due to strict control of nosocomial transmission, our
cohort tended to contract RSV late, which might account for
better outcomes. Our low incidence of NIPCs is intriguing,
and could be biased by the fact that 66% of our cohort was on
 2 immunosuppressors. Our ﬁndings support prompt
treatment of high-risk patients with inhaled ribavirin/IVIG to
diminish early RSV-related mortality and morbidity.Figure 1. Bacterial foodborne infections among post-transplant HCT patients
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Background: Diarrhea, abdominal pain and fever are
common among patients undergoing hematopoietic stem
cell transplant (HCT), but such symptoms are also typical
with foodborne infections. The burden of disease caused by
foodborne infections in patients undergoing HCT is
unknown. We sought to describe the incidence of post-
transplant bacterial foodborne infections in a single-center
population of HCT recipients.
Methods: We reviewed all patients who received a HCT at
the Fred Hutchinson Cancer Research Center in Seattle, WA
from 2001 to 2011. Data were collected retrospectively using
center databases, which include information from trans-
plant, on-site examinations, outside records, and collected
laboratory data. Patients were considered to have a bacterial
foodborne illness if Campylobacter jejuni/coli, Salmonella,
Shigella, Yersinia or Listeria species were isolated in culture;
patients with evidence of non-foodborne origin for infection
were excluded. All post-transplant events were classiﬁed as
early ( 100 days post-transplant) or late (>100 days).
Results: A total of 18/4404 (0.4%) patients developed a post-
transplant bacterial foodborne illness (Figure 1). Patients had
a mean age at infection of 45.8 years (range 1 e 68), and the
majority were adults18 years of age (n¼14 [78%]) and male
gender (n¼13, [72%]). Most cases occurred in patients who
had undergone an allogeneic transplant (n¼12 [67%]).
These infectious episodes occurred at a median of 87.5 days
after transplant (IQR 19, 367). The overall incidence rate
post-transplant was 0.34 per 100,000 patient days, and 1.9
per 100,000 in the early post-transplant period. Bacterial
foodborne infections occurred evenly between the early
and late periods (n¼9 early, n¼9 late). The most frequent
pathogen detected was Campylobacter (n¼9 [50 %])
followed by Salmonella (n¼5 [28%]), Yersinia (n¼2 [11%])
and Listeria (n¼2 [11%]); no cases of Shigella were
detected. Diagnoses were made in most patients through
positive stool cultures (n¼13 [72%]), while a smaller
proportion were ﬁrst positive through blood cultures (n¼4
[22%]); one patient was positive simultaneously at both
sites. Mortality due to bacterial foodborne illness was not
observed during follow-up.
Conclusions: Our large single-center study indicates that
bacterial foodborne infections were a rare complication
following HCT. These data provide important baseline inci-
dence for future studies evaluating dietary interventions in
HCT patients.295
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Objective: Invasive fungal infections are a cause of mortality
in pediatric allogeneic hematopoietic cell transplantation
(allo-HCT) recipients. Prophylaxis with triazoles present
a challenge in patients with non-malignant disorders due to
pre-HCT risk for organ dysfunction. Micafungin is an echi-
nocandin with activity against Candida and Aspergillus
species. Limited toxicity and drug interactions of micafungin
make this an attractive option. Limited experience has been
reported in pediatric HCT patients with non-malignant
disorders. We report our experience with daily micafungin
antifungal prophylaxis in pediatric allo-HCT patients with
non-malignant disorders.
Methods: A retrospective descriptive analysis of 28 pediatric
patients with a variety of non-malignant disorders undergoing
allo-HCT and prophylaxis with micafungin is provided. The
median age at allo-HCT was 5 years (range, 0.4-11). No patient
had a previous invasive fungal infections, hepatic, or renal
dysfunction except for one patient with hepatic ﬁbrosis. Cyclo-
sporine was used for graft-versus-host disease prophylaxis.
Results: Table 1 provides a summary of results associated
with daily micafungin antifungal prophylaxis. Micafungin
was discontinued in one patient due to liver function test
abnormalities. A baseline elevation in AST, ALT, and
bilirubin was documented in 25%, 39%, and 0% of patients;
respectively. There was a two-fold increase in AST, ALT, and
bilirubin in 60%, 67%, and 85% of patients during
treatment; these decreased on therapy. A similar trend was
noted in renal function. Cyclosporine levels did not
ﬂuctuate signiﬁcantly during therapy.
Conclusion: Daily micafungin prophylaxis is awell-tolerated
method which may prevent fungal infections in pediatric
allo-HCT patients with non-malignant disorders. Further
study of micafungin prophylaxis to evaluate the efﬁcacy of
micafungin in the prevention of fungal infections in pediatric
allo-HCT recipients with non-malignant disorders is needed.
